Abstract
Forty-one women with non-metastatic but locally advanced breast cancer were treated by modified radical or radical mastectomy, and were then randomized to receive one of two adjuvant chemotherapy regimens. Regimen A consisted of 6 months of cyclophosphamide, adriamycin, and fluorouracil (CAF) followed by 6 months of cyclophosphamide, methotrexate, fluorouracil, vincristine, and prednisone (CMFVP). Regimen B was 12 months of CMFVP. Patients were stratified for estrogen-receptor status, and all patients with a positive estrogen receptor value received tamoxifen 20 mg bid in addition to the chemotherapy. Eight of 21 patients radomized to Regimen A are alive and free of disease, whereas only 1 of 20 patients on Regimen B is well. A trend toward improved disease-free survival favoring Regimen A was observed (P = .05), although a significant difference in overall survival has not been demonstrated. Our findings support the continued study of adriamycin-containing regimens in the adjuvant setting and in combined modality therapy of locally advanced breast cancer.
This is a preview of subscription content, log in via an institution to check access.
References
Bonadonna G, Brusamolino E, Valagussa P, et al.: Combination chemotherapy as an adjuvant treatment in operable breast cancer. New Engl J Med 294: 405–410, 1979
Fisher B, Redmond C, Fisher E and participating NSABP investigators: The contribution of recent NSABP clinical trials of primary breast cancer therapy to an understanding of tumor biology — an overview of findings. Cancer 46: 1009–1025, 1980
Cooper RG, Holland JF, Glidewell O: Adjuvant chemotherapy of breast cancer. Cancer 44: 793–798, 1979
Knight WA III, Rivkin SE, Glucksberg H, et al.: Adjuvant therapy of breast cancer; the Southwest Oncology Group experience. Breast Cancer Res Treat 3 (Suppl 1): 27–33, 1983
Hoogstraten B, Fabian C: A reappraisal of single drugs in advanced breast cancer. Cancer Clin Trials 2: 101–109, 1979
Buzdar AU, Blumenschein GR, Gutterman JU, et al.: Postoperative adjuvant chemotherapy with fluorouracil, doxorubicin, cyclophosphamide, and BCG vaccine. JAMA 242: 1509–1513, 1979
Fracchia AA, Evans JF, Eisenberg BL: Stage III carcinoma of the breast. Ann Surg 192: 705–710, 1980
Bruckman JE, Harris JR, Levene MB, Chaffey JT, Hellman S: Results of treating stage III carcinoma of the breast by primary radiation therapy. Cancer 43: 985–993, 1979
Rubens RD, Sexton S, Tong D, Winter PJ, Knight RK, Hayward JL: Combined chemotherapy and radiotherapy for locally advanced breast cancer. Europ J Cancer 16: 351–356, 1980
Loprinzi CL, Carbone PP, Tormey DG, et al.: Aggressive combined modality therapy for advanced local-regional breast carcinoma. J Clin Oncol 2: 157–163, 1984
DeLena M, Varini M, Zucali R, et al.: Multimodal treatment for locally advanced breast cancer. Cancer Clin Trials 4: 229–236, 1981
Hortobagyi GN, Blumenschein GR, Spanos W, et al.: Multimodal treatment of locoregionally advanced breast cancer. Cancer 51: 763–768, 1983
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Casper, E.S., Guidera, C.A., Bosl, G.J. et al. Combined modality treatment of locally advanced breast cancer: Adjuvant combination chemotherapy with and without doxorubicin. Breast Cancer Res Tr 9, 39–44 (1987). https://doi.org/10.1007/BF01806692
Issue Date:
DOI: https://doi.org/10.1007/BF01806692